The four TCGA-based molecular prognostic groups of endometrial carcinoma (EC), ie, POLE-
mutant, mismatch repair (MMR)-deficient, p53-abnormal, and “no specific molecular …

The landscape of diagnosing and treating endometrial cancer is undergoing a profound
transformation due to the integration of molecular analysis and innovative therapeutic …

Background Risk-assessment of endometrial cancer (EC) is based on clinicopathological
factors and molecular subgroup. It is unclear whether adding hormone receptor expression …

Endometrial carcinoma (EC) can be divided into 4 prognostic molecular subtypes, and no
specific molecular profile (NSMP) type is the most commonly occurring type (∼ 50%) …

Purpose Using next generation sequencing (NGS), The Cancer Genome Atlas (TCGA)
found that endometrial carcinomas (ECs) fall under one of four molecular subtypes, and a …

Background Racial disparities in outcomes exist in endometrial cancer (EC). The
contribution of ancestry‐based variations in germline pathogenic variants (gPVs) is …

Background We sought to determine the prevalence of germline pathogenic variants (gPVs)
in unselected patients with endometrial cancer (EC), define biallelic gPVs within tumors, and …

Mullerian clear cell carcinoma (CCC) is often aggressive and chemoresistant. The
prognostic significance of molecular subclassification of endometrioid carcinomas is well …

Analyzed endometrial cancer (EC) genomes have allowed for the identification of molecular
signatures, which enable the classification, and sometimes prognostication, of these …

The dual‐stratified pathway of endometrial carcinomas (ECs) has long been dominant.
However, in 2013, The Cancer Genome Atlas (TCGA) defined four EC subgroups with …